Lord's Mark Industries Limited

This disclosure is a regulatory filing submitted to BSE Limited under Regulation 30 of SEBI LODR Regulations, serving as an update to the company's previous disclosure dated 08 June 2026.

The document concerns proceedings before the Hon'ble High Court of Delhi in the matter of Bennett Coleman and Company Limited (BCCL/Times of India) vs. Lord's Mark Industries Limited & Ors. As recorded before the court, the company has undertaken to issue 10,28,483 equity shares to Bennett Coleman and Company Limited (Times of India) at a conversion price of ₹158 per equity share.

This share issuance is in accordance with the Share Cum Warrant Subscription Agreement dated 01 August 2023. The company is honoring its contractual obligation and court undertaking by proceeding with the share issuance at the agreed valuation.

Key Developments

  • Share Issuance Details: 10,28,483 equity shares issued to BCCL at ₹158 per share
  • Total Transaction Value: Approximately ₹16.25 crore (10,28,483 shares × ₹158)
  • Legal Context: Matter before Hon'ble High Court of Delhi, continuation of disclosure dated 08 June 2026
  • Agreement Reference: Share Cum Warrant Subscription Agreement dated 01 August 2023

Current Status

The company has initiated the necessary process for obtaining listing and trading approval from BSE Limited for the 10,28,483 equity shares issued to BCCL. The application along with requisite regulatory formalities is presently under process. The company is taking all necessary steps to ensure timely completion of the listing process and commencement of trading of these shares.

Management Commentary

Sachidanand Upadhyay, Managing Director, commented that this development reflects confidence in Lord's Mark's long-term vision, business fundamentals, and growth potential. He stated that the company remains committed to building a future-ready enterprise while creating sustainable value for shareholders.

Company Business

Lord's Mark Industries Limited has established a diversified presence across healthcare, diagnostics, MedTech, dialysis, renewable energy, and advanced medical technologies.